![EMJ Dermatology 9 [Supplement 1] 2021 Front Cover](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/12/EMJ-Dermatology-9-Supplement-1-2021-Front-Cover.jpg)
At the 2020 European Academy of Dermatology and Venerology (EADV) Virtual Congress, data for 5-year efficacy and safety of tildrakizumab in adults with moderate-to-severe plaque psoriasis were presented across six posters. Overall, it was shown that tildrakizumab has a very favourable long-term efficacy and safety profile.
Latest articles
All articles
13 Mins
15
Dec
Impaired Mitochondrial and Metabolic Function of Fibroblasts Derived from Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) and junctional EB (JEB) are inherited disorders characterised by fragility and blistering of epithelial…